In this expert perspective from Hawaiian Eye 2024, Rishi P. Singh, MD, discusses how the management of retinal vein occlusion will evolve over the next year.
Singh said that the biggest change will involve the use of dual therapy with faricimab after its FDA approval in 2023.
“Faricimab is a newer drug which affects both angiopoietin-2 as well as VEGF pathways, and we’re excited to see the outcome of patients for this practice,” he said.